Immunologic and clinical effects of targeting PD-1 in lung cancer (Q38201196)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on April 2014

Language	Label	Description	Also known as
English	Immunologic and clinical effects of targeting PD-1 in lung cancer	scientific article published on April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

2 references

26 October 2020

17 October 2022

Immunologic and clinical effects of targeting PD-1 in lung cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

2 references

26 October 2020

17 October 2022

programmed cell death 1

1 reference

15 December 2019

drug delivery system

1 reference

26 October 2020

cell-mediated immunity

1 reference

PubMed publication ID

1 reference

based on heuristic

inferred from title

author name string

R D Harvey

1

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

language of work or name

0 references

publication date

1 April 2014

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

1 August 2014

9 references

3 April 2019

18 June 2019

19 June 2019

25 June 2019

31 July 2019

15 December 2019

1 June 2020

26 October 2020

17 October 2022

Clinical Pharmacology & Therapeutics

10 references

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

3 April 2019

18 June 2019

19 June 2019

25 June 2019

31 July 2019

15 December 2019

1 June 2020

26 October 2020

17 October 2022

96

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

2

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

214-223

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

9 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

18 June 2019

Europe PubMed Central

19 June 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

31 July 2019

Europe PubMed Central

15 December 2019

Europe PubMed Central

1 June 2020

Europe PubMed Central

26 October 2020

Europe PubMed Central

17 October 2022

on focus list of Wikimedia project

0 references

PD-1 as a potential target in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

State of the science: an update on renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Programmed death ligand 2 in cancer-induced immune suppression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Immunological response as a source to variability in drug metabolism and transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

The potential for crizotinib in non-small cell lung cancer: a perspective review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Biochemical mechanisms of cisplatin cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Cancer despite immunosurveillance: immunoselection and immunosubversion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

23 June 2018

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

31 August 2018

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

31 August 2018

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

31 August 2018

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.74

21 January 2018

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.74

21 January 2018

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685326

1 October 2018

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/24690569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24690569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24690569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/CLPT.2014.74

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5685326

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38201196&oldid=2201397378"